OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 6.44 EUR -1.53% Market Closed
Market Cap: 141.3m EUR

OSE Immunotherapeutics SA
Investor Relations

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Dr. Nicolas Poirier Ph.D.
General Director, CEO, Scientific Director & Director
No Bio Available
Dr. Anne-Marie Dominique Costantini M.D.
Founder & Director of Development & Strategy
No Bio Available
Ms. Anne-Laure Autret-Cornet
CFO, Administrative & Financial Director and Employee Shareholder Representative Director
No Bio Available
Mr. Alexis Peyroles
Consultant
No Bio Available
Dr. Alain Chatelin M.D.
Medical Director
No Bio Available
Bérangère Vasseur M.D.
Chief Medical Officer Immuno-Oncology
No Bio Available
Mr. Julien Perrier
Chief Commercial Officer
No Bio Available
Ms. Linda Lebon M.Sc.
Chief Regulatory Officer
No Bio Available
Dr. Silvia Comis M.D.
Head of Clinical Development
No Bio Available
Mr. Jean-Jacques Mention
Chief Business Officer
No Bio Available

Contacts

Address
PAYS DE LA LOIRE
Nantes
22, boulevard Benoni Goullin
Contacts
+33228291010.0
ose-immuno.com